What factors impact the clinical outcome of magnetic resonance imaging–guided focused ultrasound thalamotomy for essential tremor?

Kenji Fukutome, MD,1 Yoshihiro Kuga, MD, PhD,1 Hideyuki Ohnishi, MD, PhD,1 Hidehiro Hirabayashi, MD, PhD1,2 and Hiroyuki Nakase, MD, PhD3

1Department of Neurosurgery, Ohnishi Neurological Center, Akashi, Hyogo; 2Department of Neurosurgery, National Hospital Organization Nara Medical Center, Nara; 3Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan

OBJECTIVE Magnetic resonance imaging–guided focused ultrasound (MRgFUS) is a novel and useful treatment for essential tremor (ET); however, the factors impacting treatment outcome are unknown. The authors conducted this study to determine the factors affecting the outcome of MRgFUS.

METHODS From May 2016 through August 2017, 15 patients with ET were admitted to Ohnishi Neurological Center and treated with MRgFUS. To determine the factors impacting treatment outcome, the authors retrospectively studied correlations between the Clinical Rating Scale for Tremor (CRST) improvement rate and age, disease duration, baseline CRST score, skull density ratio (SDR), skull volume, maximum delivered energy, or maximum temperature.

RESULTS The mean CRST score was 18.5 ± 5.8 at baseline and 4.6 ± 5.7 at 1 year. The rate of improvement in the CRST score was 80% ± 22%. Younger age and lower baseline CRST score were correlated with a higher CRST improvement rate (p = 0.025 and 0.007, respectively). To obtain a CRST improvement rate ≥ 50%, a maximum temperature ≥ 55°C was necessary. There was no correlation between SDR and CRST improvement rate (p = 0.658). A lower SDR and higher skull volume required significantly higher maximum delivered energy (p = 0.014 and 0.016, respectively). A higher maximum temperature was associated with a significantly larger lesion volume (p = 0.026).

CONCLUSIONS Younger age and lower baseline CRST score were favorable outcome factors. It is important to assess predictive factors when applying MRgFUS.

https://thejns.org/doi/abs/10.3171/2020.2.JNS192814

KEYWORDS focused ultrasound; thalamotomy; essential tremor; clinical rating scale for tremor; magnetic resonance imaging guided; ventral intermediate nucleus; skull density ratio; temperature; functional neurosurgery

Essential tremor (ET) is the most common movement disorder in adults, with an estimated prevalence of 0.5%–5%.1,2 Although ET is not a life-threatening condition, it can profoundly impact the quality of life of patients with severe symptoms.3,4 Patients report difficulty with everyday tasks such as eating, drinking, handwriting, and dressing. Many patients also experience social embarrassment regarding their tremor. Some will refrain from dining in public, and others will retire from employment early because of disabling symptoms. Medical therapy, particularly beta-blockers and primidone, is the first-line treatment for ET; however, medication alone is often insufficient to control severe symptoms and can have undesirable side effects. If resistance to medications develops or side effects are unacceptable, neurosurgical intervention is considered, primarily targeting the nucleus ventralis intermedius of the thalamus (Vim), a component of tremor circuitry that connects the cerebellum with cortical motor pathways. Conventionally, either deep brain stimulation or radiofrequency (RF) thalamotomy has been performed for patients with ET. These two surgical therapies effectively suppress tremor,3–25 but relatively few patients choose surgery because of the perceived invasiveness of the burr holes and intracerebral electrodes.

Magnetic resonance imaging–guided focused ultrasound (MRgFUS) has recently been developed as a treatment for brain diseases. Its effectiveness for the treatment of ET was first reported in a 2016 randomized controlled
improvement has varied. There have been no detailed re-
studies, the rate of improvement among patients showing
the clinical outcome of MRgFUS for ET.

Ports on the relation between patient or treatment factors
of Helsinki. Written consent was obtained from the pa-
tients at the time of treatment.

From May 2016 through August 2017, 15 consecutive
patients with clinically significant refractory ET were
admitted to Ohnishi Neurological Center. We referred
to the study eligibility criteria of Elias et al.31 “Clinically
significant” tremor in the dominant hand was defined as
a score > 2 on the postural or action item on the Clin-
ical Rating Scale for Tremor (CRST), ranging from 0 to
4 (higher scores indicating worse tremor). “Refractory”
tremor was defined as persistent disabling tremor despite
more than 6 months of medical treatment. In all patients,
the dominant hand was the more severely affected extrem-
ity and was targeted for treatment. The exclusion criteria
were previous stereotactic or cranial surgery, other neu-
rodegenerative condition, unstable cardiac conditions,
substance abuse, current or past psychiatric disease, and
a skull density ratio (SDR; ratio of cortical to cancellous
bone) < 0.30.

Surgical Procedure

The MRgFUS procedure was performed in a 1.5-T
MRI unit (Signa HDxt with a 16-channel head/neck/spine
(HNS) coil, GE Healthcare Japan) using the ExAblate
Neuro 4000 system (Insightec), which includes a hemi-
spheric, 650-kHz, 1024-element phased-array transducer.
In addition, CT scanning (Optima CT660 Pro 0.625-mm
helical scan, GE Healthcare Japan) was performed on the
day before treatment to measure the SDR and detect calci-
ﬁed structures. Daily quality assurance was performed as
a calibration using the phantom on both the day before and
day of treatment.

Before the procedure, the patient’s head hair was com-
pletely shaved to prevent irregular reﬂection of ultrasound,
followed by attachment of the stereotactic frame to the pa-
tient’s head under local anesthesia. At this time, the frame
was symmetrically attached, with the front pins placed just
above the eyebrows and the rear pins placed on the supe-
rior nuchal line to obtain the maximum skull area. After
attaching a rubber membrane, the patient was transferred
to the MRI couch and connected to an ultrasonic trans-
ducer. After circulating chilled, degassed water between
the head and the transducer, we determined the target with
T2-weighted MRI and planned treatment by fusing an MR
image with a preoperative CT image. Typically, the target
was the contralateral Vim, which was 10.5–11 mm lateral
from the third ventricle wall and 5–5.5 mm behind the
midpoint of the intercommissural line at the level of the
midcommissural point. After treatment planning, a series
of low-power sonications conﬁrmed accurate focusing
in three orthogonal planes by means of MR thermogra-
phy. We also ascertained any adverse effects on the pa-

tient between sonications while gradually escalating the
energy. When the temperature of the target had risen to
\( \geq 55^\circ \text{C} \), which was the therapeutic temperature, the treat-
ment was completed when improvement of the tremor was
determined according to the patient’s manual drawing and
writing performance, after which the frame was removed.

In cases of inadequate improvement of symptoms, the fo-
cus of acoustic energy was moved posteriorly or inferiorly
within a range of 1 mm in each coordinate. MR images
were obtained immediately after treatment and 1 day, 1
month, and 1 year after treatment. The volume of the le-

dion was determined based on the markedly hyperintense
lesion that is the cytotoxic edema region described as zone
2 (including zone 1) by Wintermark et al. on 2-mm slice
T2-weighted images.32 The spheroid volume formula 4/3
\( \pi \times (x/2) \times (y/2) \times (z/2) \) was used to calculate lesion
volume.

Assessment of Effectiveness

We retrospectively evaluated the CRST improvement
rate of the 15 patients with medically refractory ET who
had been treated with MRgFUS and followed up for 1
year. The CRST improvement rate was calculated using
the following equation: [(baseline CRST score – 1-year
CRST score)/baseline CRST score] \times 100. Here, “CRST
score” refers to the tremor score in the affected hand. The
total score was calculated by adding the scores for CRST
part A in the affected hand (resting, postural, and action
tremor; 0–4 for each item) and the scores for CRST part B
in the affected hand (drawing of two Archimedes’ spirals
and straight lines, handwriting, and pouring water; 0–4
for each item).27 The affected hand scores ranged from 0
to 32, with a higher score indicating a more severe tremor.
We evaluated correlations between the CRST improve-
mement rate and various factors and between the factors.

Statistical Analysis

Statistical analyses were performed using ystat 2018
(Igaku Tosho Shuppan). Spearman’s correlation test was
used to analyze the correlations. The F-test was used to
analyze the scattering of correlations between SDR and
delivered sonication energy. We considered a \( p < 0.05 \)
to indicate statistical significance.

Results

Patient Characteristics and Treatment Factors

The 15 patients consisted of 4 women and 11 men, in-
cluding one left-handed man (Table 1). The mean age was
62.9 ± 11.3 years (mean ± standard deviation), with a range
from 41 to 82 years. The mean disease duration was 21.5
± 14.0 years, with a range from 2 to 47 years. The mean
baseline CRST score was 18.5 ± 5.8, with a range from 11 to 28. The mean SDR was 0.45 ± 0.11, with a range from 0.30 to 0.80. The mean skull volume was 219 ± 42 cm³, with a range from 171 to 336 cm³. The mean maximum delivered sonication energy was 16,275 ± 8610 J, with a range from 4791 to 33,018 J. The maximum mean temperature was 57.3 °C ± 1.9 °C, with a range from 54 °C to 60 °C. The mean lesion volume at 1 day after treatment was 68.0 ± 29.8 mm³, with a range from 19.7 to 141.8 mm³. In 5 patients, we could not measure lesion volume at 1 year given the disappearance of the lesion (lesion volume = 0 mm³).

**Clinical Outcome and Adverse Events**

Clinical outcome was evaluated according to the change in CRST score. The mean CRST score at 1 year after operation was 4.6 ± 5.7, and the improvement rate was 80% ± 22% (Fig. 1). Tremor was improved immediately after treatment, and the improvement was sustained for 1 year. In 8 of the 15 patients, tremor improved by over 90%, and the effect persisted for 1 year. Tremor control was unsatisfactory in 1 patient. Nine patients reported headache, vomiting, or dizziness during treatment. One patient developed ataxia but improved 8 months later. One patient had a permanent adverse effect of numbness of the lips.

**Factors Affecting Clinical Outcome**

We investigated the factors affecting clinical outcome (Table 2). Only age and baseline CRST score significantly affected clinical outcome. Younger patients had a better outcome (p = 0.025, r² = 0.269, y = 144.406 – 1.024x).

Patients with lower baseline CRST scores also had better outcomes (p = 0.007, r² = 0.544, y = 132.413 – 2.829x). In 1 patient, the maximum temperature remained at 54°C and the CRST improvement rate was only 35.7%. All other patients attained a maximum temperature ≥ 55°C and had a CRST improvement rate ≥ 50%. Lower maximum temperature was correlated with a higher CRST improvement rate except for the 1 patient with a maximum temperature of 54°C (p = 0.023, r² = 0.353, y = 461.121 – 6.574x). Disease duration, SDR, skull volume, number of elements used, and maximum delivered sonication energy were not correlated with the CRST improvement rate (p = 0.429, 0.657, 0.227, 0.566, and 0.652, respectively). Younger age was correlated with a lower baseline CRST score (p = 0.003, r² = 0.380, y = 0.317x – 1.438). Figure 2A shows the

---

**TABLE 1. Summary of patient characteristics and treatment factors**

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (yrs)</th>
<th>Sex</th>
<th>Disease Duration (yrs)</th>
<th>Baseline CRST Score</th>
<th>Tx Side</th>
<th>SDR</th>
<th>Skull Vol (cm³)</th>
<th>No. of Elements Used</th>
<th>Max Delivered Sonication Energy (J)</th>
<th>Max Temperature (°C)</th>
<th>Lesion Vol (mm³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>64</td>
<td>M</td>
<td>43</td>
<td>15</td>
<td>Lt</td>
<td>0.42</td>
<td>216</td>
<td>948</td>
<td>16,937</td>
<td>57</td>
<td>113.3</td>
</tr>
<tr>
<td>2</td>
<td>64</td>
<td>M</td>
<td>8</td>
<td>15</td>
<td>Lt</td>
<td>0.42</td>
<td>226</td>
<td>956</td>
<td>12,471</td>
<td>56</td>
<td>72.2</td>
</tr>
<tr>
<td>3</td>
<td>82</td>
<td>M</td>
<td>36</td>
<td>24</td>
<td>Lt</td>
<td>0.43</td>
<td>239</td>
<td>961</td>
<td>17,792</td>
<td>56</td>
<td>64.0</td>
</tr>
<tr>
<td>4</td>
<td>58</td>
<td>M</td>
<td>5</td>
<td>25</td>
<td>Lt</td>
<td>0.44</td>
<td>307</td>
<td>972</td>
<td>13,709</td>
<td>60</td>
<td>83.5</td>
</tr>
<tr>
<td>5</td>
<td>74</td>
<td>M</td>
<td>27</td>
<td>23</td>
<td>Lt</td>
<td>0.48</td>
<td>201</td>
<td>953</td>
<td>14,552</td>
<td>58</td>
<td>55.8</td>
</tr>
<tr>
<td>6</td>
<td>45</td>
<td>F</td>
<td>10</td>
<td>15</td>
<td>Lt</td>
<td>0.39</td>
<td>247</td>
<td>984</td>
<td>14,646</td>
<td>56</td>
<td>34.4</td>
</tr>
<tr>
<td>7</td>
<td>67</td>
<td>F</td>
<td>2</td>
<td>28</td>
<td>Lt</td>
<td>0.30</td>
<td>232</td>
<td>927</td>
<td>33,018</td>
<td>54</td>
<td>19.7</td>
</tr>
<tr>
<td>8</td>
<td>57</td>
<td>F</td>
<td>36</td>
<td>11</td>
<td>Lt</td>
<td>0.49</td>
<td>224</td>
<td>920</td>
<td>8,019</td>
<td>55</td>
<td>43.0</td>
</tr>
<tr>
<td>9</td>
<td>53</td>
<td>F</td>
<td>47</td>
<td>14</td>
<td>Lt</td>
<td>0.39</td>
<td>269</td>
<td>966</td>
<td>32,211</td>
<td>56</td>
<td>68.5</td>
</tr>
<tr>
<td>10</td>
<td>65</td>
<td>M</td>
<td>16</td>
<td>15</td>
<td>Lt</td>
<td>0.36</td>
<td>171</td>
<td>912</td>
<td>10,098</td>
<td>58</td>
<td>78.2</td>
</tr>
<tr>
<td>11</td>
<td>59</td>
<td>M</td>
<td>21</td>
<td>15</td>
<td>Lt</td>
<td>0.35</td>
<td>193</td>
<td>923</td>
<td>10,803</td>
<td>59</td>
<td>55.6</td>
</tr>
<tr>
<td>12</td>
<td>67</td>
<td>M</td>
<td>10</td>
<td>16</td>
<td>Lt</td>
<td>0.46</td>
<td>249</td>
<td>894</td>
<td>17,236</td>
<td>56</td>
<td>54.1</td>
</tr>
<tr>
<td>13</td>
<td>41</td>
<td>M</td>
<td>21</td>
<td>12</td>
<td>Lt</td>
<td>0.41</td>
<td>202</td>
<td>917</td>
<td>28,694</td>
<td>58</td>
<td>77.8</td>
</tr>
<tr>
<td>14</td>
<td>78</td>
<td>M</td>
<td>15</td>
<td>22</td>
<td>Lt</td>
<td>0.80</td>
<td>303</td>
<td>945</td>
<td>4,791</td>
<td>60</td>
<td>59.7</td>
</tr>
<tr>
<td>15</td>
<td>70</td>
<td>M</td>
<td>26</td>
<td>28</td>
<td>Rt</td>
<td>0.54</td>
<td>336</td>
<td>930</td>
<td>9,151</td>
<td>60</td>
<td>141.8</td>
</tr>
<tr>
<td>Mean</td>
<td>62.9</td>
<td></td>
<td>21.5</td>
<td>18.5</td>
<td></td>
<td></td>
<td>0.45</td>
<td>219</td>
<td>16,275</td>
<td>57.3</td>
<td>68.0</td>
</tr>
</tbody>
</table>

Tx = treatment.
The SDR, maximum delivered energy, skull volume, number of elements, and maximum mean temperature were not correlated with the CRST improvement rate.

**Discussion**

Federau et al. showed that the volume of tissue in which the thermal dose reached at least a 240-minute dose (dose$_{240}$), which is the generally accepted threshold above which total necrosis is observed, lesion volume immediately posttreatment and 1 year later was correlated with clinical outcome.\(^{29}\) They concluded that a dose$_{240}$ that will result in a total lesion volume of 36 mm$^3$ and a lesion of 11 mm$^3$ in the Vim after 1 year is necessary to maintain an improvement of more than 15 points in the CRST hand score after 1 year. In contrast, Tsolaki et al. reported that there was no correlation between lesion volume and CRST improvement rate at 1 month and 1 year.\(^{33}\) Hariz and Hirabayashi also reported that there was no correlation between lesion volume and clinical outcome in cases of RF thalamotomy.\(^{34}\) Five patients in our study showed remarkable effects (CRST improvement rates of 50%–100%) even though there was no obvious coagulation lesion after 1 year. Therefore, we considered that a large lesion volume was not always required to achieve a sufficient clinical effect. Moreover, Boutet et al. showed that lesions larger than 170 mm$^3$ were associated with an increased risk of acute adverse effects.\(^{35}\) From the above considerations, we believe that it is important that a lesion be formed at the optimal site even if the lesion volume is

**TABLE 2. Effect of different factors on clinical outcome**

<table>
<thead>
<tr>
<th>Factor</th>
<th>p Value</th>
<th>$r^2$</th>
<th>y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.025</td>
<td>0.269</td>
<td>144.406 - 1.024x</td>
</tr>
<tr>
<td>Disease duration</td>
<td>0.429</td>
<td>0.048</td>
<td>72.472 + 0.349x</td>
</tr>
<tr>
<td>Baseline CRST score</td>
<td>0.007</td>
<td>0.544</td>
<td>132.413 - 2.829x</td>
</tr>
<tr>
<td>SDR</td>
<td>0.657</td>
<td>0.022</td>
<td>92.687 - 28.532x</td>
</tr>
<tr>
<td>Skull volume</td>
<td>0.227</td>
<td>0.060</td>
<td>51.396 + 0.130x</td>
</tr>
<tr>
<td>No. of elements used</td>
<td>0.566</td>
<td>0.009</td>
<td>2.512 + 0.082x</td>
</tr>
<tr>
<td>Max delivered energy</td>
<td>0.652</td>
<td>0.000</td>
<td>78.760 + 0.000x</td>
</tr>
<tr>
<td>Max temperature</td>
<td>0.279</td>
<td>0.031</td>
<td>197.723 - 2.056x</td>
</tr>
<tr>
<td>Max temperature ≥55°C</td>
<td>0.023</td>
<td>0.353</td>
<td>461.121 - 6.574x</td>
</tr>
</tbody>
</table>

Boldface type indicates statistically significant results.

**FIG. 2.**  **A:** Relation between SDR and the delivered energy of all sonifications that reached ≥ 55°C in all the treatments. SDR was negatively correlated with the delivered energy ($p = 0.014$, $r^2 = 0.3857$, $y = 37975e^{-2.615x}$). In cases with an SDR < 0.45, the required delivered energy was significantly more scattered than in the cases with an SDR ≥ 0.45 ($p = 0.015$). **B:** There was a positive correlation between skull volume and maximum delivered energy ($p = 0.016$, $r^2 = 0.372$, $y = 2.1893x^{1.6352}$).
small and that an unnecessarily large lesion only increases adverse effects.

It is well known that the degree of temperature increase is crucial for successful treatment during thermal lesioning. For example, 1 second at 57°C and 3.5 seconds at 55°C are known to be sufficient for tissue necrosis, whereas a maximum temperature of 54°C requires 7 seconds for tissue necrosis.\(^{36,37}\) In our study, the target temperature was \(\geq 55°C\), but the duration of maximum temperature did not matter. All patients who could attain a maximum temperature \(\geq 55°C\) had a CRST improvement rate \(\geq 50\%\). The reason that there was a correlation between lower maximum temperature and higher CRST improvement rate is unknown. However, it is assumed that 55°C is a high enough temperature for successful treatment.

Krishna et al. evaluated factors that correlated with clinical outcome from another point of view. They concluded that tractography-guided targeting was safe and that the short-term outcome was good (mean CRST improvement rate at 3 months: 55.7\%).\(^{38}\) This outcome is not better than the outcome of our study; however, their method should be taken into consideration for safer treatment.

Sinai et al. reported that sex, age, disease duration, and tremor scores did not correlate with clinical outcome.\(^{28}\) On the other hand, younger age and lower baseline CRST score were correlated with a higher CRST improvement rate in our study. It is easy to predict that a lower baseline CRST score is likely to improve, and since younger patients had a higher CRST improvement rate as well. Given the abovementioned results, it is advisable to administer early treatment if a patient has some difficulties in activities of daily life and the patient wants to undergo treatment. Chang et al. reported that skull volume and SDR were positively and negatively correlated, respectively, with maximum mean temperature.\(^{36}\) They also reported that an SDR \(> 0.45\) may predict a lower energy requirement, and an SDR \(\geq 0.45\) was one of the inclusion criteria in a previous randomized controlled study.\(^{26,28}\) An SDR \(\geq 0.45\) may be reasonable for stable treatment. Boutet et al. reported that a lower SDR was correlated with higher maximum delivered energy but not with clinical outcome.\(^{29}\) Therefore, they considered that a lower SDR was not a non-conformity factor for MRgFUS. In our study, skull volume and SDR were positively and negatively correlated, respectively, with maximum mean temperature.\(^{36}\) The amount of required energy varies if SDR is \(< 0.45\), and it is difficult to predict the temperature rise. However, regardless of the SDR values and skull volume, if there is the required energy, the target maximum mean temperature will be achieved; thus, SDR and skull volume are not considered to be correlated with maximum mean temperature. Actually, many patients in our study whose SDR was \(< 0.4\) underwent MRgFUS and had a successful outcome. However, if the SDR is \(< 0.4\), the temperature rise is not stable; therefore, it was considered difficult to predict the effect of MRgFUS.

Our study has some limitations. First, it was a retrospective study. Second, changes in the target during treatment were not considered, which may have affected lesion volume and clinical outcome. Finally, it is possible that the CRST improvement rate after 1 year did not reflect the true effect of MRgFUS. Because some recurrence may happen 1 year after treatment, outcomes at 1 or 3 months may be more appropriate for evaluating the outcome.

Conclusions

Younger age and lower baseline CRST score were correlated with a better outcome. SDR was not always correlated with the CRST improvement rate. Evaluation of patient factors before treatment is beneficial for the selection of patients.

Acknowledgments

We would like to thank Enago for the English language review.

References


**Disclosures**

This study was partially supported by Insightec, which assisted only by calculating SDR.

**Author Contributions**


**Correspondence**

Kenji Fukutome: Ohnishi Neurological Center, Akashi, Hyogo, Japan. kenjifukutome82@gmail.com.